Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response

Publisher： Karger

E-ISSN： 1423-0399|86|3|256-260

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.86, Iss.3, 2011-01, pp. : 256-260

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study with 3rd- or 4th-Line Bendamustine (Flat Dose) Therapy in Patients with Metastatic Breast Cancer

By  

Oncology Research and Treatment, Vol. 32, Iss. 8-9, 2009-07 ,pp. : 488-492

Karger

Access to resources Recommend Favorite

Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer

By  

Case Reports in Oncology, Vol. 4, Iss. 1, 2011-01 ,pp. : 16-18

Karger

Access to resources Recommend Favorite

Targeted Therapy in the Treatment of Metastatic Renal Cell Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 122-131

Karger

Access to resources Recommend Favorite

Clinical experience with sunitinib dose escalation in metastatic renal cell carcinoma

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 11, Iss. 3, 2015-09 ,pp. : e1-e5

John Wiley & Sons Inc

Access to resources Recommend Favorite

Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line

By  

Oncology, Vol. 89, Iss. 6, 2015-10 ,pp. : 319-331

Karger

Access to resources Recommend Favorite